🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

White House says 15 million COVID-19 shots will roll out to children by next week

Published 11/01/2021, 11:57 AM
Updated 11/01/2021, 07:11 PM
© Reuters. FILE PHOTO: Bridgette Melo, 5, reacts as she holds the hand of her father, Jim Melo, during her inoculation of one of two reduced 10 ug doses of the Pfizer BioNtech COVID-19 vaccine during a trial at Duke University in Durham, North Carolina September 28,
PFE
-
MRNA
-
BNTX
-

By Ahmed Aboulenein and Alexandra Alper

WASHINGTON (Reuters) -The United States is rolling out Pfizer/BioNTech COVID-19 vaccines for children aged 5 to 11 this week, but most of the 15 million shots being shipped initially are unlikely to be available before next week, the White House said on Monday.

Millions of doses specifically formulated for children of that age group will start arriving at distribution centers over the next few days, White House coronavirus response coordinator Jeff Zients said, and the federal government has purchased enough supply for all eligible 28 million children.

"We are ready to execute, pending CDC's decision. And starting the week of November 8th, our vaccination program for kids ages 5 through 11 will be running at full strength," Zients told reporters at a briefing.

The U.S. Food and Drug Administration on Friday authorized the Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) coronavirus vaccine for children aged 5 to 11 years, making it the first COVID-19 shot for young children in the United States.

The U.S. Centers for Disease Control and Prevention still needs to advise on how the shot should be administered, which will be decided after a group of outside advisers discuss the plan on Tuesday.

Following the CDC's decision, parents will be able to visit vaccines.gov and filter locations offering the vaccine for the children, Zients said.

"The whole plan is based on Pfizer vaccines," he said.

Moderna (NASDAQ:MRNA) Inc said on Sunday it would delay filing its request for an emergency use authorization for a half-strength 50-microgram dose of the vaccine for children ages 6 to 11.

Shares in Moderna fell 2.3%, or $8.04, to $337.17 on Monday while Pfizer shares were off 10 cents at $43.64.

At the end of last week, the seven-day average number of coronavirus cases dropped 3% to around 69,000 daily cases, the average hospitalization rate fell 10% to around 5,100 cases, and the daily deaths average fell 10% to around 1,100, CDC Director Dr. Rochelle Walensky said at the same briefing.

© Reuters. FILE PHOTO: Bridgette Melo, 5, reacts as she holds the hand of her father, Jim Melo, during her inoculation of one of two reduced 10 ug doses of the Pfizer BioNtech COVID-19 vaccine during a trial at Duke University in Durham, North Carolina September 28, 2021 in a still image from video. Video taken September 28, 2021. Shawn Rocco/Duke University/Handout via REUTERS

U.S. Chief Medical Advisor Dr. Anthony Fauci said it was "very likely" everyone would be able to get a vaccine booster shot "within a reasonable amount of time."

Currently the CDC recommendations for boosters cover specific categories of people.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.